uniQure N.V. Announces Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants

uniQure N.V. announces public offering of ordinary shares and warrants, led by Leerink Partners, subject to market conditions.

Quiver AI Summary

uniQure N.V. has announced the initiation of an underwritten public offering of its ordinary shares and pre-funded warrants. The company plans to offer all securities in the offering and is considering granting the underwriters a 30-day option for an additional 15% of ordinary shares at the public offering price. The offering is subject to market conditions, and details regarding the final terms will be disclosed in a prospectus supplement to be filed with the SEC. uniQure is recognized for its advancements in gene therapy, particularly for conditions such as hemophilia B, and is working on therapies for diseases like Huntington's and ALS. Forward-looking statements within the release outline uncertainties regarding the offering and business conditions.

Potential Positives

• uniQure has announced an underwritten public offering of ordinary shares and pre-funded warrants, indicating the company is seeking to raise capital for further development.
• The offering includes an option for underwriters to purchase additional shares, which could potentially increase the total capital raised.
• This move follows the successful approval of uniQure’s gene therapy for hemophilia B, demonstrating the company’s ongoing commitment to advancing gene therapies for severe medical needs.
• The press release provides transparent communication regarding the process and details of the offering, enhancing investor trust and engagement.

Potential Negatives

• The announcement of a public offering may signal to investors that the company is in need of additional capital, potentially raising concerns about its financial stability.
• The offering's completion is subject to market conditions and other uncertainties, which may indicate volatility in the company's stock price and investor sentiment.
• The inclusion of significant cautionary statements about forward-looking risks could imply that the company anticipates challenges ahead, which may undermine investor confidence.

FAQ

What is uniQure's latest public offering?

uniQure has announced an underwritten public offering of ordinary shares and pre-funded warrants to purchase ordinary shares.

Who is managing the public offering for uniQure?

Leerink Partners is acting as the bookrunning manager for uniQure's proposed public offering.

Where can I find the prospectus for the offering?

The preliminary prospectus supplement will be available on the SEC's website and may be obtained from Leerink Partners.

What treatments is uniQure developing?

uniQure is advancing gene therapies for Huntington's disease, temporal lobe epilepsy, ALS, Fabry disease, and more.

Are there any risks associated with the public offering?

Yes, the offering is subject to market conditions and there are uncertainties regarding completion and financial markets.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$QURE Insider Trading Activity

$QURE insiders have traded $QURE stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $QURE stock by insiders over the last 6 months:

• MATTHEW C KAPUSTA (CEO, Managing Director) has traded it 2 times. They made 0 purchases and 2 sales, selling 103,418 shares.
• CHRISTIAN KLEMT (Chief Financial Officer) sold 1,796 shares.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$QURE Hedge Fund Activity

We have seen 65 institutional investors add shares of $QURE stock to their portfolio, and 54 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• BOXER CAPITAL, LLC added 2,225,000 shares (+inf%) to their portfolio in Q3 2024
• MILLENNIUM MANAGEMENT LLC added 1,674,760 shares (+325.1%) to their portfolio in Q3 2024
• ABRDN PLC added 1,528,581 shares (+381.7%) to their portfolio in Q3 2024
• FRANKLIN RESOURCES INC added 1,492,962 shares (+inf%) to their portfolio in Q3 2024
• ADAR1 CAPITAL MANAGEMENT, LLC removed 1,222,676 shares (-100.0%) from their portfolio in Q3 2024
• MARSHALL WACE, LLP added 1,086,578 shares (+2780.5%) to their portfolio in Q3 2024
• POINT72 ASSET MANAGEMENT, L.P. added 752,889 shares (+336.1%) to their portfolio in Q3 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced an underwritten public offering of its ordinary shares and pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to 15% additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Leerink Partners is acting as the bookrunning manager for the proposed offering.

The securities described above are being offered by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 filed with the U.S. Securities Exchange Commission (the “SEC”) on January 7, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website at

http://www.sec.gov

. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at +1 (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – a historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the completion, timing, and size of uniQure’s anticipated public offering, the grant to the underwriters of an option to purchase additional securities, and other statements identified by words such as "estimate," "plan," "project," "forecast," "intend," "will," "shall," "expect," "anticipate," "believe," "seek," "target," "continue," "could," "may," "might," "possible," "potential," "predict" and similar words or expressions.

Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms, or at all, continued interest in our rare disease portfolio, the ability to develop our product candidates and technologies, the impact of changes in the financial markets and global economic conditions, and other factors described under the heading "Risk Factors" in uniQure’s periodic securities filings with the SEC, including our Annual Report on Form 10-K filed February 28, 2024, our Quarterly Report on Form 10-Q filed November 5, 2024, the preliminary prospectus supplement once filed with the SEC and the accompanying prospectus, and other filings that uniQure makes with the SEC from time to time. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and uniQure assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.